Studieninformationen
Kurztitel:
BMS CA224-047
Beschreibung:
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Studiendesign:
Phase II/III, , Peer Reviewed, Multizentrisch, International
Therapielinien:
,
Alter:
>= 12 Jahre
Erkrankungen:
Ein-/Ausschlusskriterien:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses Exclusion Criteria: Participants must not have active brain metastases or leptomeningeal metastases Participants must not have uveal melanoma Participants must not have an active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
NCT-Nummer:
Eudract-Nummer:
Studienaktive Standorte
common:study_status_active
Universitätsklinikum Würzburg
97080 Würzburg
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Frau Dr. Anja Gesierich
Gesierich_A@ukw.de
Herr Tassilo Dege
Dege_T@ukw.de